Publications by authors named "A Saborowski"
Background And Aims: The outcome of patients with HCC who achieved complete response (CR) to immune-checkpoint inhibitor (ICI)-based systemic therapies is unclear.
Approach And Results: Retrospective study of patients with HCC who had CR according to modified Response Evaluation Criteria in Solid Tumors (CR-mRECIST) to ICI-based systemic therapies from 28 centers in Asia, Europe, and the United States. Of 3933 patients with HCC treated with ICI-based noncurative systemic therapies, 174 (4.
Systemic approaches in biliary tract cancers: a review in the era of multidirectional precision medicine.
Expert Opin Pharmacother
December 2024
Introduction: Despite a rising incidence, biliary tract cancers (BTCs) are still considered a rare tumor entity. The disease's subtle clinical presentation and lack of effective early detection strategies often lead to a diagnosis at an advanced or unresectable stage, where curative options are limited.
Areas Covered: This review provides an overview of current systemic therapies and emerging novel approaches for BTC.
Article Synopsis
- Immunotherapy combinations are the standard treatment for advanced hepatocellular carcinoma (HCC), with growing evidence supporting lenvatinib as a strong first-line option.
- A retrospective study analyzed 412 patients treated with either atezolizumab/bevacizumab (AZ/BV) or lenvatinib (LEN) across 18 European hospitals, revealing that those on AZ/BV experienced longer progression-free survival.
- Despite comparable survival rates between the two treatments overall, AZ/BV posed a higher risk of liver issues in patients with pre-existing liver function impairment, highlighting the need for careful patient monitoring.
Article Synopsis
- Preclinical studies suggest that combining MEK inhibition with autophagy or CDK4/6 targeting may be beneficial for pancreatic cancer (PDAC) patients.
- A retrospective analysis of 34 patients treated with trametinib combined with hydroxychloroquine (THCQ) or palbociclib (TP) was conducted to evaluate the effectiveness of these regimens.
- Results showed that both combinations were ineffective, with most patients experiencing disease progression within a short time frame, highlighting the need for better treatment strategies for advanced PDAC with specific genetic mutations.